# The ROYAL MARSDEN

NHS Foundation Trust

### INTRODUCTION

- · Recruitment to clinical trials can be challenging and slower than anticipated.
- Understanding patients' (pts) attitudes towards research and the factors which influence their decision regarding clinical trial participation may lead to improved trial recruitment strategies.

### **METHODS**

- Pts approached about participation in any clinical trial in the Gastrointestinal and Lymphoma Unit at the Royal Marsden (RM) between August 2013 - July 2014 were included in this prospective pt survey.
- Primary endpoint: the proportion of patients who agreed to participate in one or more clinical trials.
- Pts received a questionnaire when they consented or declined a trial (one questionnaire per trial).
- The questionnaire included multiple choice, Likert and free text questions on cancer research and
- reasons for trial participation. Information on pt demographics was collected from pt records.

### **RESULTS**

## Table 1: Patient demographics (n = 276)

Characteristic				
Age	Median 64 years (19 – 85)			
Gender	68% male 32% female			
Ethnicity	86% white, 8% Asian, 3% black			
Occupation/social class	Retired: 40% Upper middle/middle: 20% Skilled working: 12% Working: 17%			
Type of cancer	Colorectal: 43% Oesophagogastric: 36% Pancreaticobiliary: 11% Lymphoma: 10%			
Treatment aim	Curative: 35% Palliative: 65%			
Performance status	0: 41% 1: 50% 2: 8% 3: 1%			
No. of previous lines of treatment	0: 48% 1: 32% 2: 14% 3+: 6%			
Time to travel to RM*	< 1 hour: 71% 1-2 hours: 22% 2+ hours: 5% unknown: 2%			
* Only pts who completed the	questionnaire			


# Patients' perspectives of clinical trials at the Royal Marsden

Moorcraft SY1, Marriott C1, Peckitt C1, Bottero D1, Cunningham D1 and Rao S1

<sup>1</sup> The Royal Marsden NHS Foundation Trust, London and Surrey, UK.

## RESULTS: CLINICAL TRIAL PARTICIPATION


Figure 1: Recruitment to clinical trials and the pt survey



hange in diagnosis/treatment plan (n = 4), no available tissue (n = 3), deterioration in performance status (n=3)

Key: CTIMP = clinical trial of an investigational medicinal product, Pre-screening = molecular testing to determine

#### Figure 2: The reason pts identified as the most important influence on their decision to participate in the trial



IInknown

Table 2: Factors which influenced pts' decision to participate in a clinical trial

Reason	CTIMP	Pre- screening	Non- CTIMP	All
	n = 63	n = 28	n = 150	n=241
Pt felt the trial offered the best available treatment	78%	57%	39%	51%
Pt felt the trial result could benefit others	84%	86%	96%	92%
Pt wanted to contribute to scientific research	59%	57%	74%	68%
Pt felt they would be monitored more closely	44%	32%	28%	33%
Pt felt they would have better quality care	32%	18%	16%	20%
Pt's family were keen for pt to participate	38%	29%	13%	22%
Pt trusted the doctor treating them	60%	36%	49%	50%
Pt felt that otherwise cancer will get worse	27%	11%	9%	14%

Note: Pts were asked to indicate all the factors which influenced their decision to participate

Reasons why pts declined a clinical trial:


- Did not wish to have the study drug, additional procedures or any further
- Did not feel well enough or felt too anxious/overwhelmed by cancer diagnosis.
- Did not wish to have placebo or thought the standard treatment was more

#### RESULTS: PATIENTS' VIEWS ON CANCER RESEARCH

 96% of pts who consented to a trial were happy to have been approached about participating in cancer research 99% of pts believe cancer research will

help doctors better understand and treat

Figure 3: Pts' views on the use and storage of blood and tissue samples



■ Concerns about storage

■ No concerns about


sample use and

sample use and

Trial information:

- 90% of pts rated the verbal information they received about the trial as excellent/good.
- 90% of pts stated the pt information sheet was easy to understand.

Figure 4: Pts' views on donating tissue for genetic research (even if not told their genetic results)



National Institute for Health Research

Figure 5: Pts' response to the question "Would you participate in a trial that required a repeat biopsy?"




Table 3: Logistic regression analysis of factors affecting pts' views on research biopsies

Would enter trial with repeat biopsy	Yes (n=78)	No (n=48)	p-value*
Age: < 65yrs	37 (56.9)	28 (43.1)	
≥ 65yrs	41 (67.2)	20 (32.8)	0.236
Performance Status: 0	30 (66.7)	15 (33.3)	
1	36 (59.0)	25 (41.0)	0.423
2	7 (70.0)	3 (30.0)	0.839
Number of previous lines of			
treatment: o	24 (47.1)	27 (52.9)	
1	31 (67.4)	15 (32.6)	0.045
2+	22 (78.6)	6 (21.4)	0.009
Type of treatment: Curative	18 (46.2)	21 (53.9)	
Palliative	60 (69.0)	27 (31.0)	0.015
CTIMP trial: No	44 (60.3)	29 (39.7)	
Yes	19 (52.8)	17 (47.2)	0.457
Pre-screening	15 (88.2)	2 (11.8)	0.043

\* P-values compare the ues/no proportion to that for the top line in each group

Proportion of pts who would have been happy to consent to the trial on the day of receiving the information sheet:

- CTIMP trials: 54%
- Pre-screening trials: 79%
- Non-CTIMP trials: 66%

## CONCLUSIONS

- · The majority of pts approached consented to one or more clinical trials and many pts wish to help others or contribute to research.
- A high proportion of pts were willing to donate tissue for research and consider trials involving repeat biopsies.
- Available clinical trials should be discussed with pts.

Acknowledgements: NIHR Biomedical Research Centre at the Royal Marsden Hospital & Institute of Cancer Research

> Contact: sheela.rao@rmh.nhs.uk singyu.moorcraft@rmh.nhs.uk

